Emerging studies suggest Retatru tide , a dual activator targeting both incretin and another hormone, could represent a notable development for obesity loss . Preliminary patient trials have demonstrated substantial reductions in abdominal fat , potentially surpassing existing obesity medications . Nevertheless , further evaluation is required to c